EE9900387A - (E)-4,6-dikloro-3-(2-okso-1-fenüülpürrolidiin-3-ülideenmetüül)-1H-indool-2-karboksü ülhappe naatriumisoola kristallhüdraat - Google Patents

(E)-4,6-dikloro-3-(2-okso-1-fenüülpürrolidiin-3-ülideenmetüül)-1H-indool-2-karboksü ülhappe naatriumisoola kristallhüdraat

Info

Publication number
EE9900387A
EE9900387A EEP199900387A EEP9900387A EE9900387A EE 9900387 A EE9900387 A EE 9900387A EE P199900387 A EEP199900387 A EE P199900387A EE P9900387 A EEP9900387 A EE P9900387A EE 9900387 A EE9900387 A EE 9900387A
Authority
EE
Estonia
Prior art keywords
phenylpyrrolidin
ylidenemethyl
indole
dichloro
oxo
Prior art date
Application number
EEP199900387A
Other languages
English (en)
Inventor
Cimarosti Zadeo
Maragni Paolo
Original Assignee
Glaxo Wellcome S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome S.P.A. filed Critical Glaxo Wellcome S.P.A.
Publication of EE9900387A publication Critical patent/EE9900387A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EEP199900387A 1997-03-05 1998-03-03 (E)-4,6-dikloro-3-(2-okso-1-fenüülpürrolidiin-3-ülideenmetüül)-1H-indool-2-karboksü ülhappe naatriumisoola kristallhüdraat EE9900387A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound
PCT/EP1998/001146 WO1998039327A1 (en) 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Publications (1)

Publication Number Publication Date
EE9900387A true EE9900387A (et) 2000-04-17

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900387A EE9900387A (et) 1997-03-05 1998-03-03 (E)-4,6-dikloro-3-(2-okso-1-fenüülpürrolidiin-3-ülideenmetüül)-1H-indool-2-karboksü ülhappe naatriumisoola kristallhüdraat

Country Status (29)

Country Link
EP (1) EP0966463A1 (et)
JP (1) JP2001513796A (et)
KR (1) KR20000075907A (et)
CN (1) CN1249750A (et)
AP (1) AP9901637A0 (et)
AR (1) AR011178A1 (et)
AU (1) AU6825198A (et)
BG (1) BG103779A (et)
BR (1) BR9808305A (et)
CA (1) CA2282851A1 (et)
CO (1) CO4940415A1 (et)
EA (1) EA199900710A1 (et)
EE (1) EE9900387A (et)
GB (1) GB9704498D0 (et)
HR (1) HRP980114A2 (et)
HU (1) HUP0002109A2 (et)
ID (1) ID24207A (et)
IL (1) IL131489A0 (et)
IS (1) IS5166A (et)
NO (1) NO994303L (et)
NZ (1) NZ337315A (et)
OA (1) OA11154A (et)
PE (1) PE51399A1 (et)
PL (1) PL335652A1 (et)
SK (1) SK119699A3 (et)
TR (1) TR199902117T2 (et)
WO (1) WO1998039327A1 (et)
YU (1) YU43499A (et)
ZA (1) ZA981791B (et)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
RU2020100230A (ru) 2017-06-12 2021-07-13 Глитек Ллс. Лечение депрессии антагонистами nmda и антагонистами d2/5-ht2a или селективными антагонистами 5-нт2a

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
CN1249750A (zh) 2000-04-05
BG103779A (en) 2000-06-30
WO1998039327A1 (en) 1998-09-11
HRP980114A2 (en) 1998-12-31
YU43499A (sh) 2000-12-28
ID24207A (id) 2000-07-13
TR199902117T2 (xx) 2000-03-21
NZ337315A (en) 2001-02-23
OA11154A (en) 2003-04-16
AP9901637A0 (en) 1999-09-30
AR011178A1 (es) 2000-08-02
IS5166A (is) 1999-08-27
SK119699A3 (en) 2000-05-16
CA2282851A1 (en) 1998-09-11
CO4940415A1 (es) 2000-07-24
JP2001513796A (ja) 2001-09-04
NO994303L (no) 1999-11-03
PL335652A1 (en) 2000-05-08
NO994303D0 (no) 1999-09-03
IL131489A0 (en) 2001-01-28
EP0966463A1 (en) 1999-12-29
EA199900710A1 (ru) 2000-04-24
AU6825198A (en) 1998-09-22
KR20000075907A (ko) 2000-12-26
BR9808305A (pt) 2000-05-16
GB9704498D0 (en) 1997-04-23
HUP0002109A2 (hu) 2001-04-28
PE51399A1 (es) 1999-06-07
ZA981791B (en) 1999-09-03

Similar Documents

Publication Publication Date Title
IS1946B (is) Kristallað form af ómeprasólnatríumsalti
NO20013665L (no) Kaliumsalt av (S)-omeprazol
DE59912742D1 (de) Substituierte pyrazolderivate
EE200000720A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
NO20003451D0 (no) 2,3-substituerte indolforbindelser som cox-2 inhibitorer
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
NO20010331L (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20003615D0 (no) FremgangsmÕte for korreksjon av brønn-loggedata
EE9900387A (et) (E)-4,6-dikloro-3-(2-okso-1-fenüülpürrolidiin-3-ülideenmetüül)-1H-indool-2-karboksü ülhappe naatriumisoola kristallhüdraat
NO20015737L (no) Indol derivater
DE69824279D1 (de) Stabilisiertes Natriumcarbonat-Peroxyhydrat
DK1068198T3 (da) 5-Heteroarylsubstituerede indoler
NO996448D0 (no) System for intervensjon av undervannsbrønner
ATA203099A (de) Natriumvalproat-granulat mit verringerter hygroskopizität
DZ3463A1 (fr) Cristaux d'inhibiteurs de l'echangeur sodium-hydrogene de type 1
ATE232544T1 (de) Selektive inhibitoren des mmp-12
DE50013257D1 (de) Hochalkalisches kristallines Natriumsilikat
ATE414059T1 (de) Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid
ATE250025T1 (de) Hydrazin-derivate
SI0991641T1 (en) Crystalline form of omeprazole sodium salt
IT1303734B1 (it) Forma cristallina del diclofenac sale sodico.
ID21508A (id) Proses untuk pembuatan senyawa-senyawa 1-(amino-alkil) indol.